NYSE:TEVA - Teva Pharmaceutical Industries Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$24.28 +0.23 (+0.96 %)
(As of 06/20/2018 04:00 PM ET)
Previous Close$24.28
Today's Range$24.05 - $24.78
52-Week Range$10.85 - $33.82
Volume7.93 million shs
Average Volume14.10 million shs
Market Capitalization$24.63 billion
P/E Ratio6.18
Dividend Yield0.60%
Teva Pharmaceutical Industries logoTeva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. This segment also develops, manufactures, and sells active pharmaceutical ingredients. The Specialty Medicines segment provides specialty medicines for use in central nervous system and respiratory indications. Its products in the central nervous system area comprise Copaxone for the treatment of relapsing forms of MS; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. This segment's products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Qnasl, Braltus, Cinqair/Cinqaero, and Aerivio Spiromax for the treatment of asthma and chronic obstructive pulmonary disease, as well as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market. The company has collaboration arrangements with Otsuka Pharmaceutical Co. Ltd. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.

Receive TEVA News and Ratings via Email

Sign-up to receive the latest news and ratings for TEVA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations


Debt-to-Equity Ratio1.80
Current Ratio1.00
Quick Ratio0.65


Trailing P/E Ratio6.18
Forward P/E Ratio9.60
P/E Growth2.39

Sales & Book Value

Annual Sales$22.39 billion
Price / Sales1.10
Cash Flow$6.2739 per share
Price / Cash3.87
Book Value$14.86 per share
Price / Book1.63


EPS (Most Recent Fiscal Year)$3.93
Net Income$-16,265,000,000.00
Net Margins-72.36%
Return on Equity18.59%
Return on Assets5.01%


Outstanding Shares1,016,880,000

Teva Pharmaceutical Industries (NYSE:TEVA) Frequently Asked Questions

What is Teva Pharmaceutical Industries' stock symbol?

Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

How often does Teva Pharmaceutical Industries pay dividends? What is the dividend yield for Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries announced a quarterly dividend on Thursday, November 2nd. Investors of record on Tuesday, November 28th will be paid a dividend of $0.085 per share on Tuesday, December 12th. This represents a $0.34 annualized dividend and a yield of 1.40%. The ex-dividend date of this dividend is Monday, November 27th. View Teva Pharmaceutical Industries' Dividend History.

How were Teva Pharmaceutical Industries' earnings last quarter?

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) issued its earnings results on Thursday, May, 3rd. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.63 by $0.28. The company earned $5.07 billion during the quarter, compared to analyst estimates of $4.80 billion. Teva Pharmaceutical Industries had a positive return on equity of 18.59% and a negative net margin of 72.36%. Teva Pharmaceutical Industries's revenue was down 10.0% compared to the same quarter last year. During the same period last year, the firm earned $1.06 EPS. View Teva Pharmaceutical Industries' Earnings History.

When is Teva Pharmaceutical Industries' next earnings date?

Teva Pharmaceutical Industries is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for Teva Pharmaceutical Industries.

What guidance has Teva Pharmaceutical Industries issued on next quarter's earnings?

Teva Pharmaceutical Industries issued an update on its FY18 earnings guidance on Thursday, May, 3rd. The company provided earnings per share (EPS) guidance of $2.40-2.65 for the period, compared to the Thomson Reuters consensus estimate of $2.42. The company issued revenue guidance of $18.5-19.0 billion, compared to the consensus revenue estimate of $18.62 billion.

What price target have analysts set for TEVA?

27 equities research analysts have issued 1-year price objectives for Teva Pharmaceutical Industries' stock. Their predictions range from $11.00 to $41.00. On average, they expect Teva Pharmaceutical Industries' stock price to reach $20.0962 in the next twelve months. View Analyst Ratings for Teva Pharmaceutical Industries.

What are Wall Street analysts saying about Teva Pharmaceutical Industries stock?

Here are some recent quotes from research analysts about Teva Pharmaceutical Industries stock:
  • 1. According to Zacks Investment Research, "Teva beat estimates for both earnings and sales in the first quarter and also raised its 2018 outlook. Teva is facing significant challenges in the form of accelerated generic competition for Copaxone, new competition for branded products, pricing erosion in the U.S. generics business, lower-than-expected contribution from new generic launches and a massive debt load. Nonetheless, Teva has a new organizational structure in place, is closing plants, cutting down its generics portfolio, divesting non-core assets, eliminating low-value R&D projects, and aims to cut its global workforce by more than 25% over the next two years to revive growth. Its financial position seems more stable than before as it is regularly paying down debt. After declining sharply in 2017, Teva’s shares have also picked up this year. However, Teva has a long way to go before gaining stability and resumption of organic growth seems unlikely before 2019." (5/9/2018)
  • 2. Maxim Group analysts commented, "Teva reported a better than expected quarter at $5.5B in revenues versus consensus at $5.3B, but we note revenues were down sequentially (3Q17: $5.6B). Generics came in at $3.1B and higher margin specialty at $1.8B. Copaxone in particular outperformed expectations, generating $821M, which is 34% greater than the $611M expected by the street. The beat on revenues followed through to non-GAAP EPS, which was $0.93, above expectations of $0.77." (2/8/2018)
  • 3. Cantor Fitzgerald analysts commented, "This morning Teva announced more details of its new strategic plan under CEO Kare Schultz, including the layoff of 14,000 people. This is meaningfully above the Street’s estimate of 10,000 jobs." (12/14/2017)

Are investors shorting Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries saw a drop in short interest in May. As of May 31st, there was short interest totalling 49,028,870 shares, a drop of 8.5% from the May 15th total of 53,599,101 shares. Based on an average daily volume of 12,341,076 shares, the days-to-cover ratio is currently 4.0 days. View Teva Pharmaceutical Industries' Current Options Chain.

Who are some of Teva Pharmaceutical Industries' key competitors?

Who are Teva Pharmaceutical Industries' key executives?

Teva Pharmaceutical Industries' management team includes the folowing people:
  • Mr. Kåre Schultz, Pres, Chief Exec. Officer & Director (Age 57)
  • Mr. Michael McClellan, Exec. VP & CFO (Age 47)
  • Dr. Carlo de Notaristefani, Exec. VP of Global Operations (Age 60)
  • Mr. Mark Sabag, Exec. VP of Global HR (Age 47)
  • Dr. Hafrun Fridriksdottir, Exec. VP of Global R&D (Age 56)

Has Teva Pharmaceutical Industries been receiving favorable news coverage?

News stories about TEVA stock have been trending somewhat positive recently, according to Accern. Accern ranks the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Teva Pharmaceutical Industries earned a coverage optimism score of 0.05 on Accern's scale. They also assigned media headlines about the company an impact score of 45.08 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Who are Teva Pharmaceutical Industries' major shareholders?

Teva Pharmaceutical Industries' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Franklin Resources Inc. (7.19%), Polaris Capital Management LLC (0.97%), OppenheimerFunds Inc. (0.42%), Thornburg Investment Management Inc. (0.37%), Swiss National Bank (0.33%) and Barrow Hanley Mewhinney & Strauss LLC (0.28%). Company insiders that own Teva Pharmaceutical Industries stock include Brendan P O'grady, Deborah A Griffin, Mark Sabag, Michael James Mcclellan, Richard Daniell, Roberto Mignone and Sven Dethlefs. View Institutional Ownership Trends for Teva Pharmaceutical Industries.

Which institutional investors are selling Teva Pharmaceutical Industries stock?

TEVA stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Millennium Management LLC, Schroder Investment Management Group, Psagot Investment House Ltd., Clal Insurance Enterprises Holdings Ltd, State of Wisconsin Investment Board, Bellevue Group AG and Sei Investments Co.. Company insiders that have sold Teva Pharmaceutical Industries company stock in the last year include Brendan P O'grady, Deborah A Griffin, Mark Sabag, Michael James Mcclellan, Richard Daniell and Sven Dethlefs. View Insider Buying and Selling for Teva Pharmaceutical Industries.

Which institutional investors are buying Teva Pharmaceutical Industries stock?

TEVA stock was bought by a variety of institutional investors in the last quarter, including Thornburg Investment Management Inc., Polaris Capital Management LLC, Caisse DE Depot ET Placement DU Quebec, OppenheimerFunds Inc., Susquehanna Fundamental Investments LLC, CIBC World Markets Inc., New York State Common Retirement Fund and Natixis. View Insider Buying and Selling for Teva Pharmaceutical Industries.

How do I buy shares of Teva Pharmaceutical Industries?

Shares of TEVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Teva Pharmaceutical Industries' stock price today?

One share of TEVA stock can currently be purchased for approximately $24.28.

How big of a company is Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries has a market capitalization of $24.63 billion and generates $22.39 billion in revenue each year. The company earns $-16,265,000,000.00 in net income (profit) each year or $3.93 on an earnings per share basis. Teva Pharmaceutical Industries employs 51,792 workers across the globe.

How can I contact Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The company can be reached via phone at 972-3926-7267 or via email at [email protected]

MarketBeat Community Rating for Teva Pharmaceutical Industries (TEVA)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  982 (Vote Outperform)
Underperform Votes:  883 (Vote Underperform)
Total Votes:  1,865
MarketBeat's community ratings are surveys of what our community members think about Teva Pharmaceutical Industries and other stocks. Vote "Outperform" if you believe TEVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TEVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.